Thermo Fisher Scientific’s Oncomine Dx Target Test was approved as a CDx with medication for patients suffering from RET-fusion positive NSCLC. Credit: Thermo Fisher Scientific.

Japanese regulatory agency Ministry of Health, Labour and Welfare (MHLW) has approved Thermo Fisher Scientific’s Oncomine Dx Target Test as a companion diagnostic (CDx) with a lung cancer medication.

The Oncomine test was granted approval as a next-generation sequencing (NGS)-based CDx for patients suffering from RET-fusion positive non-small-cell lung cancer (NSCLC) who can be treated with Eli Lilly and Company’s selpercatinib (formerly known as LOXO-292).

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The move comes a year after MHLW granted orphan drug designation to selpercatinib.

Thermo Fisher Scientific Japan vice-president and general manager Hiroo Murota said: “This approval will help patients suffering from NSCLC whose tumours are positive for fusions in the RET receptor, providing access to new, potentially more effective treatments.

“We will continue to advance precision medicine by expanding our companion diagnostic tests that identify biomarkers associated with targeted therapies.”

The Oncomine Dx Target Test is developed to identify different specific genetic changes in tumours found in patients with non-small cell lung cancer. The lab test also helps in determining if certain medications can help in treating cancerous growth.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Thermo Fisher currently offers the NGS-based CDx solution in more than 15 countries. In Japan, the test now has approvals for five biomarkers with a total of ten associated targeted therapies for NSCLC patients.

Headquartered in Massachusetts, US, Thermo Fisher Scientific focuses on supporting life sciences research, enhancing patient diagnostics and therapies among others.

Recently, the company’s clinical sequencing unit partnered with AstraZeneca to create NGS-based companion diagnostics.

 

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact